MedWatch

Sanofi pledges to limit US price increases

The French drug group Sanofi now promises, in line with its Danish rival Novo Nordisk, to limit its price increases and ensure greater tranparency in its drug pricing on the US market.

CEO for Sanofi
Photo: Sanofi/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles